← Back to Search

Biological

PRP for Patellar Tendinitis (PRP Trial)

Phase 2
Waitlist Available
Led By Kenneth Lee, MD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Self-report failure of at least 2 of the most common treatment options for PT (e.g. NSAIDs, relative rest, ice and bracing).
Age between 18 and 39 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 16 weeks, 32 weeks, 52 weeks
Awards & highlights

PRP Trial Summary

This trial is investigating whether or not platelet-rich plasma is an effective treatment for patellar tendinopathy. Double-blinded means that neither the participants nor the researchers will know who is receiving the treatment until after the study is completed.

Eligible Conditions
  • Patellar Tendinitis

PRP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
The person has failed at least 2 of the most common treatments for PT, such as NSAIDs, relative rest, ice, and bracing.
Select...
The text states that the age range between 18 and 39 years is when people are considered to be the most productive.
Select...
The pain score is 3 or more on a 10 point scale.
Select...
does not always equate to loss of muscle bulk Not all supervised physical therapy leads to the loss of muscle bulk.

PRP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 16 weeks, 32 weeks, 52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 16 weeks, 32 weeks, 52 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Measure of Activity Level: Tegner Activity Level Score
Change in Measure of Pain Level: VISA-P Score
Change in Visual Analogue Scale (VAS) Pain Score
Secondary outcome measures
MRI Scan To Demonstrate Treatment-related Changes in Pathologic Imaging Features of PT (T2 Signal Intensity)
MRI Scan To Demonstrate Treatment-related Changes in Pathologic Imaging Features of PT (Thickness)
Ultrasound Scan to Demonstrate Treatment-related Changes in Pathologic Imaging Features of PT (Echogenicity) From Baseline
+2 more
Other outcome measures
Isokinetic Dynamometer Measure of Flexor and Extensor Muscle Strength Before and After the Intervention
Relationship Between Changes in Novel Quantitative MRI and US Parameters of PT and Clinical and Biomechanical Improvement Following Treatment.
T2* Fraction of Fast-relaxing Macromolecular-bound Water (FF)
+1 more

PRP Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Platelet-Rich Plasma (PRP)Experimental Treatment1 Intervention
Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous PRP.
Group II: Dry Needling ProcedurePlacebo Group1 Intervention
Group 2 (dry needling) will undergo US-guided dry needling procedure similar to PRP injection.
Group III: Sham ProcedurePlacebo Group1 Intervention
Group 3 (sham) will undergo US-guided sham dry needling procedure.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRP
2014
Completed Phase 4
~1860

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,182 Previous Clinical Trials
3,167,357 Total Patients Enrolled
General ElectricIndustry Sponsor
46 Previous Clinical Trials
12,367 Total Patients Enrolled
Kenneth Lee, MDPrincipal InvestigatorUniversity of Wisconsin, Madison
1 Previous Clinical Trials
20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any restrictions regarding who can enroll in this research project?

"This trial is only open to those between 18 and 39 years old who have tendinitis. A total of 30 patients are needed for this clinical study."

Answered by AI

What is the maximum risk that somebody faces when using PRP?

"PRP has undergone some testing for safety, as is common in Phase 2 trials. However, there is no data currently available supporting its efficacy."

Answered by AI

Are there any patients that you are currently enrolling for this experiment?

"This particular clinical trial, which was originally announced on April 25th, 2017, is still recruiting patients according to the latest update on July 12th, 2022."

Answered by AI

Will this research be testing elderly patients over the age of seventy?

"The age limit for this clinical trial is 18 years or older and 39 years or younger."

Answered by AI

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
University of Wisconsin, Madison
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Platelet-Rich Plasma Therapy for Patellar Tendinopathy
2017. "Platelet-Rich Plasma Therapy for Patellar Tendinopathy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03136965.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top